Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population

被引:155
作者
Bharmal, Murtuza
Thomas, Joseph, III
机构
[1] Quintiles Transnatl Corp, Falls Church, VA 22042 USA
[2] Purdue Univ, Sch Pharm, W Lafayette, IN 47907 USA
关键词
ceiling; EQ-5D; EuroQol; SF-12; SF-6D;
D O I
10.1111/j.1524-4733.2006.00108.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: The EuroQol (EQ-5D) and SF-6D (derived from the SF-12) were compared to assess any ceiling effect in the EQ-5D and the SF-6D descriptive systems. In addition, the Physical Component Summary (PCS-12), the Mental Component Summary (MCS-12) and the EuroQol Visual Analog Scale (EQ-VAS) were compared on their discriminative ability to detect differences among individuals with different morbidities and sociodemographic characteristics. Methods: Data from the 2000 Medical Expenditure Panel Survey were used for the analysis. A total of 11,248 individuals that were 18 years or older and had data on all the study variables were included in the analysis. Results: A total of 5104 individuals (47%) reported no limitations on all of the EQ-5D dimensions and only 683 (5.8%) were classified in full health based on the SF-6D descriptive system. Approximately 49% of the respondents that reported no limitations on the EQ-5D reported feeling "tense or downhearted and low," "a little," (level 2) or "some" (level 3) of the time on SF-6D. PCS-12 scores and EQ-VAS scores among individuals reporting no limitations on the EQ-5D descriptive system were significantly lower for respondents reporting coronary heart disease, angina, diabetes, myocardial infarction, high blood pressure or joint pain compared with respondents that reported no medical condition. Effect sizes for medical conditions using the PCS-12 were larger than the effect sizes using the EQ-VAS. Conclusions: Unlike the EQ-5D descriptive system, the SF-6D descriptive system derived from the SF-12 does not seem to have a ceiling effect. Nevertheless, the SF-6D does not discriminate between individuals with different morbidities who report full health on the EQ-5D, as does the PCS-12 and the EQ-VAS.
引用
收藏
页码:262 / 271
页数:10
相关论文
共 35 条
[21]   An empirical comparison of EQ-5D and SF-6D in liver transplant patients [J].
Longworth, L ;
Bryan, S .
HEALTH ECONOMICS, 2003, 12 (12) :1061-1067
[22]  
Macran S, 2003, MED CARE, V41, P218
[23]   A comparison of four indirect methods of assessing utility values in rheumatoid arthritis [J].
Marra, CA ;
Esdaile, JM ;
Guh, D ;
Kopec, JA ;
Brazier, JE ;
Koehler, BE ;
Chalmers, A ;
Anis, AH .
MEDICAL CARE, 2004, 42 (11) :1125-1131
[24]   Treatment costs in Hodgkin's disease: A cost-utility analysis [J].
Norum, J ;
Angelsen, V ;
Wist, E ;
Olsen, JA .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) :1510-1517
[25]   Determining clinically important differences in health status measures - A general approach with illustration to the Health Utilities Index Mark II [J].
Samsa, G ;
Edelman, D ;
Rothman, ML ;
Williams, GR ;
Lipscomb, J ;
Matchar, D .
PHARMACOECONOMICS, 1999, 15 (02) :141-155
[26]  
SAS Institute Inc, 2001, SAS STAT GUID PERS C
[27]   US valuation of the EQ-5D health states - Development and testing of the D1 valuation model [J].
Shaw, JW ;
Johnson, JA ;
Coons, SJ .
MEDICAL CARE, 2005, 43 (03) :203-220
[28]   SF-36 summary scores - Are physical and mental health truly distinct? [J].
Simon, GE ;
Revicki, DA ;
Grothaus, L ;
Vonkorff, M .
MEDICAL CARE, 1998, 36 (04) :567-572
[29]  
Taft C, 2001, QUAL LIFE RES, V10, P415
[30]   Do SF-36 summary component scores accurately summarize subscale scores? [J].
Taft, C ;
Karlsson, J ;
Sullivan, M .
QUALITY OF LIFE RESEARCH, 2001, 10 (05) :395-404